Cleerly
About Cleerly
Cleerly is a pioneering healthcare AI company dedicated to establishing a new standard of care for coronary artery disease (CAD) and ultimately eliminating heart attacks. The company leverages its FDA-cleared, AI-driven digital care platform to provide a comprehensive and non-invasive assessment of coronary arteries. By analyzing coronary computed tomography angiography (CCTA) images, Cleerly’s proprietary machine learning algorithms precisely quantify and characterize atherosclerotic plaque—including its volume, composition, length, and location—and evaluate stenosis severity.
This advanced phenotyping of CAD enables physicians to gain unprecedented insights into a patient’s heart health, facilitating earlier and more accurate identification of individuals at risk for heart attacks, even before symptoms manifest. Cleerly’s platform also incorporates Cleerly ISCHEMIA™, an algorithm that determines the likelihood of vessel-level ischemia, validated through multiple clinical trials against invasive fractional flow reserve (FFR). The detailed, interactive reports generated by Cleerly support clinicians in developing personalized treatment plans, optimizing patient management, and enhancing health literacy across the coronary care pathway. The company’s approach is built upon nearly two decades of foundational research and extensive clinical trials involving over 50,000 patients, ensuring a robust scientific basis for its innovative solutions.
Focus Areas
Business Intelligence
| Key Investors | Insight Partners, Battery Ventures, T. Rowe Price, Fidelity Management and Research Company, Breyer Capital, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, DigiTx Partners, Sands Capital, Piper Sandler's Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Novartis, Pura Vida Investments |
| Partnerships | Cardiac Care Alliance, Bunkerhill Health Inc. |
| Acquisitions | None |
| Technology | AI-driven platform, machine learning algorithms, cloud-native web-based software, non-invasive coronary computed tomography angiography (CCTA) analysis, 3D model generation, Cleerly PowerScribe API for radiology reporting integration |
| FDA Clearances | 2 cleared products (estimated) |
What Physicians Need to Know
Cleerly stands out for physicians by offering a paradigm shift in cardiovascular care. Its **comprehensive, AI-powered plaque analysis** provides objective, quantitative data on plaque volume, type (including high-risk soft plaque), and location, which is superior to traditional calcium scoring and stress tests for predicting heart attack risk. The **FDA-cleared Cleerly ISCHEMIA** module offers a non-invasive assessment of ischemia likelihood, validated against invasive FFR, potentially reducing the need for invasive diagnostic procedures. Physicians gain **enhanced diagnostic confidence** and the ability to formulate **highly personalized and proactive treatment plans** for patients, even those who are asymptomatic, thereby facilitating earlier intervention and heart attack prevention. The **Cleerly COMPARE** feature allows for objective, longitudinal tracking of disease progression and treatment effectiveness, providing measurable insights into patient management. Furthermore, Cleerly offers **efficient workflows** with rapid analysis times (average 1 hour 20 minutes) and interactive, web-based reports that improve both physician understanding and patient engagement. The platform's **extensive clinical validation** and growing **payer coverage** by major insurers further support its adoption and utility in clinical practice.
Cleerly supports various methods for CCTA data upload, including direct upload, the Nuance Powershare network, Intelerad Inteleshare, and Cleerly Proxy (a cloud-based solution). It also provides a PowerScribe API for integration with radiology reporting solutions like PowerScribe 360 and PowerScribe One, streamlining existing hospital and practice workflows.
What the Web Says
Cleerly generally receives positive feedback for its innovative AI-powered cardiovascular disease detection technology, with users appreciating its ability to provide detailed, actionable insights beyond traditional methods. However, some employer reviews indicate challenges with management communication and workload, particularly during periods of rapid growth.
Overall: MixedStrengths
- Advanced AI for precise cardiovascular disease detection
- Provides detailed, actionable insights for treatment
- Improves diagnostic accuracy compared to traditional methods
- Positive impact on patient care and outcomes
- Strong scientific foundation and clinical validation
- Innovative technology in the healthcare space
Limitations
- Management communication issues cited in some employer reviews
- Workload can be demanding, especially during growth phases
- Potential for rapid changes in company direction
- Some employees feel undervalued or unheard
- Specific product cons not widely available from public reviews
- Integration challenges with existing healthcare systems (speculative, not explicitly stated in reviews)
Based on reviews from: Glassdoor, Reddit, Healthcare IT News (various articles/mentions), Company press releases/news
Last updated: 2026-07-17
Videos
News, demos, and interviews about Cleerly.
Videos load interactively. If none appear, search YouTube for Cleerly →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Cleerly.
Comparisons
Related Companies
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]
Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]
Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]
Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]
Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]